GLUT1 is a protein that moves glucose from your bloodstream into your cells. It sits embedded in cell membranes throughout the body and acts as a gateway, allowing glucose to pass through without requiring energy. In adults, its most critical job is feeding two tissues that depend almost entirely on glucose: the brain and red blood cells. When GLUT1 doesn’t work properly, the consequences are primarily neurological, a condition known as GLUT1 deficiency syndrome.
How GLUT1 Works
GLUT1 belongs to a family of glucose transporters, but it’s unique in being present on virtually every tissue in the body. It handles what’s called “basal” glucose uptake, the baseline delivery of sugar that keeps cells running at all times, regardless of insulin levels. Unlike the glucose transporter in muscle and fat tissue (GLUT4), which only activates when insulin signals it, GLUT1 works constantly.
The protein operates through facilitated diffusion. When glucose concentration is higher on one side of a cell membrane than the other, GLUT1 lets glucose flow down that concentration gradient, no energy input required. This makes it efficient but also means it can move glucose in either direction. In the liver, for example, GLUT1 handles bidirectional glucose transport depending on whether the body needs to store or release sugar.
Where GLUT1 Is Most Active
During early development, GLUT1 is widespread and highly expressed in proliferating cells throughout an embryo. It plays a direct role in embryo implantation by ramping up in the uterine lining and the outer cells of the early embryo, driven by estrogen and progesterone. It also regulates glucose transfer from mother to fetus across the placenta.
After birth, GLUT1 concentrations remain high in the brain, skeletal muscle, and heart muscle during infancy. As a child grows, expression drops in most tissues (replaced by more specialized transporters) but stays elevated in the brain. This is why GLUT1 problems hit the brain hardest: it’s one of the few organs that never switches to a backup transporter.
GLUT1 is especially concentrated at blood-tissue barriers, the tightly sealed boundaries that control what enters sensitive organs. The blood-brain barrier, blood-retinal barrier, and blood-nerve barrier all rely heavily on GLUT1 to shuttle glucose across their endothelial cells. In the eye alone, GLUT1 appears in retinal pigment cells, lens fiber cells, and the blood vessels of the iris.
The Red Blood Cell Connection
Human red blood cells carry an extraordinarily high density of GLUT1, more than 200,000 molecules per cell, making up roughly 10% of the total protein in their membranes. This seems like overkill for cells that could get glucose through simpler means, and researchers have found a surprising explanation. In red blood cells, GLUT1 preferentially transports a form of vitamin C (dehydroascorbic acid) rather than glucose. Humans are among the few mammals that can’t manufacture their own vitamin C, so this high GLUT1 expression on red blood cells evolved as a workaround, helping absorb and recycle the vitamin from the bloodstream.
GLUT1 Deficiency Syndrome
When mutations in the SLC2A1 gene (the gene that encodes GLUT1) reduce the protein’s function, glucose can’t cross the blood-brain barrier efficiently. The result is GLUT1 deficiency syndrome, a neurological condition where the brain is chronically starved of its primary fuel. About 90% of cases arise from new, spontaneous mutations rather than being inherited from a parent. When it does run in families, the pattern is autosomal dominant, meaning a single copy of the mutated gene is enough to cause symptoms.
The condition was once considered exceptionally rare, with fewer than 500 known patients worldwide. That estimate has been revised dramatically upward. GLUT1 mutations account for roughly 1% of generalized epilepsies and up to 10% of absence epilepsies. Current projections put the number of affected people at 3,400 to 4,500 in the United States and around 105,000 globally, suggesting most cases go undiagnosed.
Symptoms and How They Progress
Symptoms follow a predictable age-related pattern. In early infancy, the most common first sign is seizures that don’t respond to standard epilepsy medications. The second most common early feature is distinctive abnormal eye-head movements, where an infant’s eyes and head move in unusual, repetitive patterns. Head growth often slows during this period as well.
As a child grows, developmental delays become increasingly apparent. Intellectual disability ranges from mild to severe, generally proportional to the overall severity of the condition. All affected individuals have some degree of speech impairment. In adolescence and adulthood, movement disorders often become the dominant problem, including difficulty with coordination (ataxia) and episodes of involuntary muscle contractions triggered by physical exertion. These movement symptoms can be more disabling than the seizures in older patients.
Diagnosis
The hallmark diagnostic finding is a low ratio of glucose in the cerebrospinal fluid (the fluid surrounding the brain and spinal cord) compared to glucose in the blood. In healthy people, glucose moves freely enough into the cerebrospinal fluid to maintain a predictable ratio. In GLUT1 deficiency, that ratio drops because the transporter can’t keep up. Across studied patients, the cerebrospinal fluid-to-blood glucose ratio ranged from 0.19 to 0.59, with 91% of patients falling at or below the 10th percentile for normal values. Genetic testing of the SLC2A1 gene confirms the diagnosis and identifies the specific mutation.
Treatment With a Ketogenic Diet
The primary treatment for GLUT1 deficiency syndrome is a ketogenic diet, a high-fat, very-low-carbohydrate eating pattern. The logic is straightforward: if the brain can’t get enough glucose, give it a different fuel. When carbohydrate intake drops low enough, the liver converts fat into molecules called ketones, which cross the blood-brain barrier through a separate transporter that GLUT1 deficiency doesn’t affect. This provides the brain with an alternative energy source it can use immediately.
The diet is most effective at controlling seizures, which represent the most acute consequence of the brain’s energy deficit. Its impact on developmental and movement symptoms is less dramatic but still beneficial in many patients. Because the underlying genetic defect is permanent, dietary treatment is typically maintained long-term, though the specific formulation may be adjusted as patients age.